Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

A secure analytics platform to study the prognosis of people with HIV in the USA, Canada and Europe and comparative effectiveness of treatment regimens: the Antiretroviral Therapy Cohort Collaboration

Award Number: R01AI181733
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/07/2024
PERIOD OF PERFORMANCE END DATE: 06/30/2029

Group Awards By:

View Award Description

A secure analytics platform to study the prognosis of people with HIV in the USA, Canada and Europe and comparative effectiveness of treatment regimens: the Antiretroviral Therapy Cohort Collaboration - Modified Project Summary/Abstract Section Enter the text here that is the new abstract information for your application. This section must be no longer than 30 lines of text. Effective antiretroviral therapy (ART) dramatically changed the HIV epidemic. As ART regimens and health care for people with HIV (PWH) improve, the population of PWH in North America and Europe is aging. It is therefore important to provide up-to-date data on prognosis for PWH and compare effectiveness of modern ART regimens. The Antiretroviral Therapy Cohort Collaboration (ART-CC) is the largest collaboration of HIV cohorts across North America and Europe, with 20 HIV cohorts and data on around 250,000 PWH on ART. ART-CC pioneered standardized coding of causes of death in treated PWH and has fostered a collaborative approach to research, enabling researchers across the globe to utilize its data and methodological expertise. Approaches to analyzing data from HIV cohort collaborations have evolved with increasing awareness of the need to protect participants’ privacy, and use of data use agreements to govern data transfers. We will develop a new secure data platform enabling ART-CC collaborators and external researchers to conduct secure, privacy-protecting analyses of pseudonymized ART-CC data using reproducible, shared code. Data will be accessed in a controlled environment, with export of analysis results requiring approval from trained output checkers. This platform will facilitate a distributed model for analyses, enabling efficient analyses based on open science principles whilst cohorts retain ownership of their data. Research within the platform will incorporate 3 aims. 1) Enhance understanding of cause-specific mortality and cause-specific hospitalizations among PWH, building on ART-CC’s world-leading data on causes of death and extending these to causes of hospitalization. 2) Enhance understanding of prognosis for all-cause mortality in subgroups of PWH. 3) Estimate the comparative effectiveness of novel ART regimens versus older, more commonly used regimens and of GLP-1 agonists, which are increasingly used to address ART-associated weight gain in PWH. Our work will continue to be the main source of information on cause-specific mortality among PWH in the United States. Novel information on cause-specific hospitalizations will be similarly impactful. PWH and the health professionals responsible for their care will have access to up-to-date estimates of prognosis, aligning with NIH strategic planning for HIV Goal 1. Work on comparative effectiveness of ART regimens will contribute to improved care and better life expectancy and quality of life for PWH in the United States.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $470,636 )
2026	2026	UNIVERSITY OF BRISTOL	BEACON HOUSE	BRISTOL				GBR	Allergy and Infectious Diseases Research	000	3	7/29/2026	NON-COMPETING CONTINUATION	$470,636
														Subtotal = $470,636

Issue Date FY: 2025 ( Subtotal = $483,540 )
2025	2025	UNIVERSITY OF BRISTOL	BEACON HOUSE	BRISTOL				GBR	Allergy and Infectious Diseases Research	000	2	9/11/2025	NON-COMPETING CONTINUATION	$483,540
														Subtotal = $483,540

Issue Date FY: 2024 ( Subtotal = $494,632 )
2024	2024	UNIVERSITY OF BRISTOL	BEACON HOUSE	BRISTOL				GBR	Allergy and Infectious Diseases Research	001	1	9/4/2024	NEW	$49,263
2024	2024	UNIVERSITY OF BRISTOL	BEACON HOUSE	BRISTOL				GBR	Allergy and Infectious Diseases Research	000	1	8/7/2024	NEW	$445,369
														Subtotal = $494,632

Grand Total All Awards = $1,448,808

Top

All Categories

About

Search

Reports

Data Submission

Award Information

A secure analytics platform to study the prognosis of people with HIV in the USA, Canada and Europe and comparative effectiveness of treatment regimens: the Antiretroviral Therapy Cohort Collaboration

Award Number: R01AI181733

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/07/2024

PERIOD OF PERFORMANCE END DATE: 06/30/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer